|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A comparative quantitative biodistribution analysis with radio-labeled protein preparations revealed that a fractionated administration of L19-hIL2 could deliver comparable product doses to the tumor with decreased product concentration in blood and normal organs, compared to bolus injection.
|
31790729 |
2020 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In an orthotopic PDX model, animals receiving chemoimmunotherapy with an anti-GD2 antibody, GM-CSF, and a soluble IL15/IL15Rα complex had greater tumor regression than did those receiving chemotherapy alone (<i>P</i> = 0.012) or combined with anti-GD2 antibody and GM-CSF with (<i>P</i> = 0.016) or without IL2 (<i>P</i> = 0.035).
|
31455682 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Moreover, this process was related to donor-derived T/B cells by improving the immune microenvironment in the tumor, as demonstrated by elevated levels of interferon-γ (IFN-γ), tumor necrosis factor-α (TNF-α), interleukin-2 (IL-2), IL-6, IL-16, chemokine (C-X-C motif) ligand 10 (CXCL10), and CXCL11 and decreased levels of IL-10 and IL-4 at tumor sites.
|
31152624 |
2019 |
|
Neoplasms
|
0.400 |
GeneticVariation
|
group |
BEFREE |
Tumor bearing mice vaccinated with a GMCSF-expressing CT-26 GVAX vaccine had reduced tumor growth when given IL2-R336A before vaccination.
|
31059598 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Dysregulation of immune responses, as indicated by plasma levels of CRP, CCL4 and IL2 were found in patients with breast cancer despite the removal of the tumour mass.
|
30842160 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The reduced ability of IC35 to stimulate human βγ-IL2Rs (associated with IL2-toxicities) makes it a potential candidate for clinical trials where higher clinical IC doses might enable better tumor targeting and increased antitumor effects with less toxicity.
|
31069147 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The antibody-based delivery of certain proinflammatory payloads (such as IL2, IL12, and TNF) to the tumor microenvironment can lead to a dramatic potentiation of their anticancer activity.
|
30824549 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, IL-37 indirectly up-regulated the expression of major histocompatibility class II molecules, CD86 and CD40 on DCs by acting on tumor cells; IL-37 also indirectly enhanced the anti-tumor effect of T lymphocytes by stimulating DCs to secrete cytokines such as IL-2, IL-12, IL-12p70, interferon-α (IFN-α) and IFN-γ.
|
31410060 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Both CBD-CPI and CBD-IL-2 suppressed tumor growth compared to their unmodified forms in multiple murine cancer models, and both CBD-CPI and CBD-IL-2 increased tumor-infiltrating CD8<sup>+</sup> T cells.
|
30971453 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Transcriptional analysis of tumor biopsies showed that NKTR-214 engaged the IL2 receptor pathway and significantly increased genes associated with an effector phenotype.
|
30988166 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
This prompted experiments demonstrating that specific IL-2c binding in the tumor is limited by IL-2 secreted by tumor-resident effector cells and that extratumorally expanded T and NK cells can infiltrate the irradiated tumor, which suggests that systemic immune activation considerably contributed to the reduction of tumor growth.
|
30808414 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The efficiency of natural killer (NK) cells, adoptively transferred, for treatment against solid tumors is hindered by their difficulty to enter tumors from the blood circulation as well as their inability to prolong viability in the absence of IL-2.
|
31057396 |
2019 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
However, circulating CD57<sup>+</sup> NK cells displayed decreased CXCR3 expression and CD16A-induced IL2-dependent proliferation <i>in vitro</i> Presence of CD57<sup>+</sup> NK cells was reduced in breast tumor-associated infiltrates as compared with paired peripheral blood samples, suggesting deficient homing, proliferation, and/or survival of NK cells in the tumor niche.
|
31189644 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The tumor growth rate and recipient survival of single and triple IL-2 applications were compared with corresponding parameter values of untreated control.
|
29511983 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
While IL-2 targets anti-tumor cytotoxic lymphocytes (CTLs) for the treatment of patients with melanoma or renal cell carcinoma, IL-2 directed at regulatory T (Treg) cells could have potential therapeutic value in several immune-related diseases including chronic graft-versus-host disease (cGVHD), type 1 diabetes (T1D) and systemic lupus erythematosus (SLE).
|
30415086 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Treatment with TAB004 + Lip-MSA-IL-2 resulted in significantly improved survival and slower tumor growth compared to controls in MUC1.Tg mice bearing an orthotopic PDA.MUC1 tumor.
|
31114758 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
In a sequential dual-therapy study in tumors that have progressed for 10 days, both s-DAB-IL-2(V6A) and s-DAB-IL-2 given before checkpoint inhibition with anti-programmed cell death-1 (anti-PD-1) antibodies inhibited tumor growth, while either drug given as monotherapy had less effect. s-DAB-IL-2(V6A), a fully monomeric protein with reduced vascular leak, is a second-generation diphtheria-toxin-based fusion protein with promise as a cancer immunotherapeutic both alone and in conjunction with PD-1 blockade.
|
30718426 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
The authors found, by targeting VE-PTP, that the antitumor effects induced by IL-2 were augmented [tumor-free 44% (IL-2 alone) vs. 87.5% (IL-2+AKB)], associated with enhanced immune cell infiltrate (90% increase for CD8 T cells and natural killer cells).
|
31348125 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Combination immunotherapy with interleukin-2 surface-modified tumor cell vaccine and programmed death receptor-1 blockade against renal cell carcinoma.
|
30343514 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
When administered to <i>Cynomolgus</i> monkey as intravenous injection, IL2-XE114-TNF<sup>mut</sup> showed the expected plasma concentration of ~1,500 ng/ml at early time points, indicating the absence of any <i>in vivo</i> trapping events, and a half-life of ~2 h. IL2-XE114-TNF<sup>mut</sup> may thus be considered as a promising biopharmaceutical for the treatment of metastatic clear-cell renal cell carcinoma, since these tumors are known to be sensitive to IL2 and to TNF.
|
31799191 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Besides the genetic vaccines composed by tumor extracts and lipoplexes carrying human interleukin-2 and granulocyte-macrophage colony-stimulating factor genes, the patients were subjected to combined treatment received in the post-surgical bed injections of lipid-complexed thymidine kinase suicide gene plus ganciclovir and canine interferon-β gene plus bleomycin.
|
30858538 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
A detailed high-parametric single-cell analysis of the tumor leukocyte composition revealed that F8-IL2 had a strong impact on NK-cell activity without collateral immune activation in the systemic immune compartment, whereas CTLA-4 blockade led to significant changes in the T-cell compartment.
|
30782667 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
After intravenous injection to melanoma bearing mice, NV-DOX<sub>IL-2</sub> can accumulate in tumor and remarkably suppress tumor growth with negligible systemic toxicity.
|
30831276 |
2019 |
|
Neoplasms
|
0.400 |
Biomarker
|
group |
BEFREE |
Tumour cell survival is supported by IL-2 and there is a skew towards CD8-positive T cells in the tumour environment, while the immune check-point protein PD-L1 is upregulated in the tumours.
|
29691476 |
2018 |
|
Neoplasms
|
0.400 |
AlteredExpression
|
group |
BEFREE |
These cellular activations resulted in upregulation of host-protective cytokines IL-2, IL-12, IL-17, tumour necrosis factor-α and interferon-γ, and downregulation of IL-4, IL-10 and tumour growth factor-β.
|
29140228 |
2018 |